Cosmos Health Sees Q3 Revenue Rise 38% to $17.1M and U.S. NOOR Sales to Exceed $12M
Cosmos Health reported Q3 2025 revenue of $17.1 million, up 38% year-over-year, and gross profit of $2.6 million, a 116% increase with a 15.21% margin. It affirmed no material operational impact from Middle East tensions and projects U.S. NOOR collagen sales to exceed $12 million over 12 months.
1. Geopolitical Resilience
Cosmos Health confirmed that ongoing conflicts in Iran and the broader Middle East have had negligible impact on its operations, supply chain, and business performance. The company emphasized the strength of its diversified platform across Europe, North America and other regions in insulating performance from regional disruptions.
2. Q3 2025 Financial Highlights
In Q3 2025, Cosmos Health achieved record revenue of $17.1 million, a 38% increase year-over-year, and gross profit of $2.6 million, up 116%, with a record gross margin of 15.21%. Adjusted EBITDA rose 74%, and the cash balance strengthened to $4.63 million from $0.66 million at the end of Q2 2025.
3. Accelerating U.S. NOOR Expansion
Sales of Sky Premium Life NOOR collagen in U.S. GMP-certified, FDA-registered facilities are underway, eliminating cross-border tariffs and logistical risks. The company forecasts gross margins of approximately 75% and anticipates NOOR revenue to exceed $12 million within the next 12 months, tapping into the $163.7 billion U.S. nutraceutical market.